In a 57-year-old woman with new‑onset uncontrolled diabetes mellitus, a normal pancreas on abdominal CT, and no personal or family history of diabetes, what additional tests should be performed to evaluate for autoimmune diabetes or other etiologies?

Testing for Autoimmune and Other Etiologies in New-Onset Adult Diabetes

In a 57-year-old woman with new-onset uncontrolled diabetes, normal pancreatic imaging, and no family history, you should immediately test for islet autoantibodies (GAD, IA-2, ZnT8, and insulin antibodies) and measure C-peptide to distinguish autoimmune diabetes from other etiologies.

Recommended Testing Algorithm

First-Line Autoantibody Panel

Test for the following islet autoantibodies 1, 2:

• Glutamic acid decarboxylase (GAD) - measure this first as the primary antibody
• Islet antigen 2 (IA-2) - if GAD is negative
• Zinc transporter 8 (ZnT8) - if GAD is negative
• Insulin autoantibodies - useful if not yet on insulin treatment

The presence of these autoantibodies indicates autoimmune diabetes, which in adults over 35 presenting without immediate insulin requirement is termed latent autoimmune diabetes in adults (LADA) 3, 4. This represents 5-10% of adult-onset diabetes cases and is characterized by slower β-cell destruction than classic type 1 diabetes.

C-Peptide Measurement

Measure C-peptide with concurrent glucose (ideally within 5 hours of eating) 2:

• <200 pmol/L (<0.6 ng/mL): Consistent with type 1 diabetes/severe β-cell deficiency
• 200-600 pmol/L (0.6-1.8 ng/mL): Indeterminate; may indicate type 1 diabetes, LADA, or MODY
• >600 pmol/L (>1.8 ng/mL): Suggests type 2 diabetes or preserved β-cell function

This test helps determine the degree of β-cell function and guides treatment decisions.

Clinical Context Matters

The AABBCC approach helps frame your evaluation 1, 2:

• Age: At 57, she's older than typical type 1 diabetes onset but LADA remains possible
• Autoimmunity: Check for personal/family history of other autoimmune conditions (thyroid disease affects 15-30% of type 1 diabetics, celiac disease 4-9%) 5
• Body habitus: BMI <25 kg/m² favors autoimmune etiology
• Background: No family history of diabetes argues against typical type 2 diabetes
• Control: Inability to achieve glycemic goals on oral agents suggests β-cell deficiency
• Comorbidities: Recent immune checkpoint inhibitor therapy can trigger autoimmune diabetes

Important Caveats

When Autoantibodies Are Negative

5-10% of adults with true type 1 diabetes are autoantibody-negative 2. If antibodies are negative but clinical features suggest autoimmune diabetes (unintentional weight loss, ketoacidosis tendency, rapid progression to insulin requirement), the diagnosis may still be type 1 diabetes. In this scenario, C-peptide becomes critical for classification.

Consider Alternative Diagnoses

Given the normal pancreatic imaging, you've already excluded:

• Pancreatic cancer (which can cause new-onset diabetes in 0.6-0.85% of older adults with NOD within 3 years) 6
• Chronic pancreatitis causing type 3c diabetes

However, do not stop here. Consider:

• Monogenic diabetes (MODY) if A1C <7.5% at diagnosis, though less likely without family history 2
• Drug-induced diabetes (corticosteroids, atypical antipsychotics, statins)
• Endocrinopathies: Screen for Cushing's syndrome, acromegaly, hyperthyroidism if clinical features present

Rare but Critical: Insulinoma

Though uncommon, if she develops hypoglycemia with declining A1C rather than persistent hyperglycemia, measure insulin and C-peptide during a hypoglycemic episode. Elevated levels during hypoglycemia indicate insulinoma 7.

Treatment Implications

The distinction between autoimmune and non-autoimmune diabetes fundamentally changes management:

• Positive autoantibodies + low C-peptide: Early insulin therapy is appropriate; oral agents will likely fail as β-cell function declines 3
• Positive autoantibodies + preserved C-peptide: May initially respond to oral agents but require close monitoring for deterioration; consider early insulin to preserve remaining β-cell function
• Negative autoantibodies + high C-peptide: Standard type 2 diabetes management with metformin and other oral agents

Monitoring Strategy

If autoantibodies are positive but C-peptide is preserved (200-600 pmol/L), repeat C-peptide testing after 3-5 years to assess progression of β-cell failure 2. This helps predict when insulin will become necessary and prevents dangerous delays in treatment escalation.

The key pitfall is misclassifying adult-onset autoimmune diabetes as type 2 diabetes, which occurs in approximately 40% of cases 1. This leads to inadequate treatment, poor glycemic control, and increased risk of diabetic ketoacidosis. Your systematic antibody and C-peptide testing prevents this error.